PressNovember 11, 2021 Alto Neuroscience Announces Publication in Nature Neuroscience Highlighting Superiority of Data-Driven Framework for Mapping Human Neurobiology Domains
PressNovember 8, 2021 Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami
PressNovember 8, 2021 Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
PressNovember 4, 2021 Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
PressNovember 3, 2021 COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
PressNovember 2, 2021 Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia
PressOctober 29, 2021 MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol through iSTRYM, MINDCURE’s Digital Therapeutics Platform
PressOctober 29, 2021 Psychedelics Venture Capital Firm Iter Investments to Exhibit/Host Events at Wonderland: Miami by Microdose from Nov. 8-9, 2021
PressOctober 29, 2021 Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
PressOctober 29, 2021 Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study using Kernel Flow Technology
PressOctober 22, 2021 Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder
PressOctober 20, 2021 Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
